---
layout: default
title: Apalutamide
parent: 僅模型預測 (L5)
nav_order: 369
evidence_level: L5
indication_count: 0
---

# Apalutamide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Apalutamide: Evaluation Incomplete — No TxGNN Predictions Available

## One-Sentence Summary

Apalutamide (DrugBank ID: DB11901) is currently not marketed in Taiwan, and this Evidence Pack contains no TxGNN-predicted new indications for evaluation.
Due to critical data gaps — including absent mechanism of action, missing safety data, and an empty predictions list — a full repurposing evaluation cannot be responsibly completed at this time.
Immediate data remediation across three blocking areas is required before proceeding.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No data (not registered in Taiwan; `original_indications` field empty) |
| Predicted New Indication | No predictions available (`predicted_indications: []`) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; no supporting studies retrieved |
| US Market Status | Not marketed in Taiwan（未上市） |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

This section cannot be completed because the Evidence Pack contains no TxGNN predictions (`predicted_indications` is an empty array). Without a predicted indication, there is no repurposing hypothesis to evaluate or justify mechanistically.

Currently, detailed mechanism of action data is also not available (Data Gap DG002). The `original_moa` field is marked as absent, meaning mechanistic bridging between any original and new indication cannot be assessed. The DrugBank query did return a record (result\_count: 1), but structured MOA fields were not extracted into the Evidence Pack.

Original indication data is likewise absent: the `original_indications` field is empty, and there are zero TFDA license records to reference. Before any mechanistic argument can be constructed, the TxGNN prediction pipeline must be re-run with this drug and the DrugBank MOA must be retrieved.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication is available to determine a relevant search query.

---

## Literature Evidence

Currently no related literature available — no predicted indication is available to determine a relevant search query.

---

## US Market Information

No Taiwan FDA authorizations on record for Apalutamide.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|--------------|-------------|---------------------|
| — | — | — | No TFDA license found |

The drug is listed as **未上市 (not marketed)** in Taiwan, with zero total licenses. US FDA approval status was not queried in this Evidence Pack and should be confirmed separately.

---

## Cytotoxicity

Apalutamide is an androgen receptor (AR) inhibitor belonging to the antineoplastic class. Although the DrugBank category field was not extracted into this Evidence Pack, the drug's pharmacological class is well-established. The cytotoxicity profile is therefore included based on drug class identification.

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — Androgen Receptor (AR) inhibitor (non-cytotoxic) |
| Myelosuppression Risk | Low (AR inhibitors do not typically cause significant myelosuppression) |
| Emetogenicity Classification | Low |
| Monitoring Items | Liver function tests, thyroid function (TSH), seizure history assessment, cardiovascular status |
| Handling Protection | Standard handling precautions for hormonal antineoplastic agents apply |

> Note: Please refer to the package insert for complete toxicity and monitoring guidance. Detailed toxicity data was not available in this Evidence Pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** Safety data was not retrieved for this Evidence Pack. Data Gap DG001 classifies the absence of TFDA package insert warnings and contraindications as **Blocking** — this issue must be resolved before any clinical or regulatory evaluation can proceed. Drug–drug interaction query returned no results (query status: `not_found`).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Apalutamide (DB11901) is critically incomplete — the TxGNN prediction pipeline produced no output, the original indication is unknown, the mechanism of action is missing, and all safety fields contain data gaps. There is currently no repurposing hypothesis to evaluate.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Download and parse the TFDA package insert PDF to extract warnings, contraindications, and original approved indication
- **[High — DG002]** Query the DrugBank API to retrieve mechanism of action, drug categories, and toxicity profile
- **[Critical]** Investigate why `predicted_indications` is empty — confirm whether the TxGNN pipeline was executed for this drug, check DrugBank mapping success, and re-run prediction if needed
- **[Required]** Verify US FDA approval status and retrieve approved indication(s) from the FDA label (Apalutamide is known to hold US approvals; these should be cross-referenced)
- **[Follow-up]** Once predictions are populated, run evidence collection against ClinicalTrials.gov and PubMed for the top predicted indication before proceeding to any further evaluation stage
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

